



SUBSECRETARÍA DE SALUD PÚBLICA
DIVISIÓN DE PLANIFICACIÓN SANITARIA
DEPARTAMENTO EVALUACIÓN DE TECNOLOGÍAS SANITARIAS Y SALUD BASADA EN EVIDENCIA

INFORME DE BÚSQUEDA Y SÍNTESIS DE COSTO-EFECTIVIDAD

Guía de Práctica Clínica

Urgencias Odontológicas Ambulatorias: Infecciones de origen dentario

EN PERSONAS CON DENTICIÓN PERMANENTE, ALÉRGICAS A LOS BETA LACTÁMICOS (PENICILINA) Y DIAGNÓSTICO DE INFECCIÓN DE ORIGEN DENTARIO CON INDICACIÓN DE PROFILAXIS ANTIBIÓTICA, ¿SE DEBE “USAR UN MACRÓLIDO (ERITROMICINA, AZITROMICINA)” EN COMPARACIÓN A “USAR UN ANTIBIÓTICO DEL GRUPO DE LINCOSAMIDAS (CLINDAMICINA)”?

Uno de los factores a considerar para formular una recomendación en Guías de Práctica Clínica con la metodología “*Grading of Recommendations Assessment, Development and Evaluation*” es la relación entre la efectividad y los costos de las intervenciones a evaluar.

BÚSQUEDA DE EVALUACIONES ECONÓMICAS

Para determinar si la evidencia de costo-efectividad de las tecnologías sanitarias era necesaria se aplicaron los siguientes criterios en conjunto con el equipo de expertos:

- Mucha variabilidad en la práctica clínica.
- Incertidumbre relevante respecto a costo efectividad de intervenciones evaluadas.
- Cambio en práctica clínica acarrea altos beneficios en términos de salud.
- El cambio en la práctica clínica puede tener un impacto relevante en costos y el presupuesto del sistema de salud.

La búsqueda consideró estudios de costo-efectividad y revisiones sistemáticas de evaluaciones de costo-efectividad del uso de un macrólido versus el uso de un antibiótico del grupo de lincosamidas, en personas con dentición permanente, alérgicas a los beta lactámicos y diagnóstico de infección de origen dentario, con indicación de profilaxis antibiótica. Se identificaron términos MESH y términos de texto libre asociados a la población. La búsqueda consideró estudios publicados en inglés y español, en las siguientes bases de datos: MEDLINE, EMABASE, COCHRANE, GOOGLE, BRISA y en el National Institute for health and Care Excellence (NICE).

Todas las estrategias de búsqueda fueron realizadas durante el año 2019.

Ver detalle en Anexo 1 “*Términos de Búsqueda y Resultados de la búsqueda*”.

SÍNTESIS DE EVIDENCIA SEGÚN PREGUNTA

Al ejecutar la búsqueda de evidencia para la pregunta, no se encontraron artículos en ninguna de las fuentes buscadas.

ANEXO 1: ESTRATEGIA DE BÚSQUEDA Y RESULTADOS DE LA BÚSQUEDA

	Términos libres	DECS	MeSH
P	Tooth, teeth, permanent tooth, permanent teeth, secondary tooth, secondary teeth, adult tooth, adult teeth, dentition, permanent, permanent dentition, dentition, secondary, secondary dentition, dentition, adult, adult dentition, penicillin allergy, penicillin allergic, allergy to penicillin, beta-lactamase allergy, β -lactam allergy, hypersensitivity, prophylaxis, antibiotic, premedication, antibiotic, antibiotic premedication, antibiotic premedications, antibiotic y antibiotic prophylaxis	diente, dientes, diente permanente, diente definitivo, diente adulto, dentición permanente, alergia a la penicilina, alergia a penicilinas, alergia a betalactámicos, hipersensibilidad, alérgico a penicilina, profilaxis antibiótica, premedicación y premedicación antibiótica	Dentition, permanent y antibiotic prophylaxis
I	Macrolides, fidaxomicin, lucensomycin, maytansine, mepartricin, miocamycin, natamycin, nystatin, oleandomycin, troleandomycin, oligomycins, rutamycin, sirolimus, everolimus, tacrolimus y tylosin	Macrolidos, fidaxomicina, lucensomicina, maitansina, mepartricin, miocamicina, natamicina, nistatina, oleandomicina, troleandomicina, oligomicina, rutamicina, sirolimus, everolimus, tacrolimus y tilosina	Macrolides
C	Lincomycin, lincosamides y clindamycin	Lincomicina, lincosamida y clindamicina	Lincosamides
O	Cost benefit analysis, cost effectiveness, cost utility analysis, economic evaluation, marginal analysis, pricing, biomedical technology assessment, health technology assessment, economics, willingness to pay, health care cost, ICER, QALY, DALY, quality adjusted life years, disability adjusted life years, incremental cost effectiveness ratio	Análisis costo beneficio, análisis costo efectividad, análisis costo utilidad, evaluación económica, análisis de precio, tecnologías biomédicas, evaluación de tecnologías, disponibilidad de pago, costos en salud, costos sanitarios, ICER, QALY, DALY, quality adjusted life years, disability adjusted life years, incremental cost effectiveness ratio, AVAC, año de vida ajustado por calidad, razón costo efectividad, año de vida ajustado por	Cost-benefit analysis, costs and cost analysis, technology assessment, biomedical

Base de datos	Fecha de búsqueda	Resultados	Resultados después de remover duplicados
Medline-Pubmed	19.08.2019	0	0
EMBASE	19.08.2019	0	0
NICE	19.08.2019	0	0
BRISA (RedETSA)	19.08.2019	0	0
COCHRANE	19.08.2019	0	0
GOOGLE	19.08.2019	0	0
Total	19.08.2019	0	0

Estrategias de Búsqueda

PUBMED

1	Dentition, permanent[MeSH Terms] or Tooth[Text Word] or Teeth[Text Word] or Permanent tooth[Text Word] or Permanent teeth[Text Word] or Secondary tooth[Text Word] or Secondary teeth[Text Word] or Adult tooth[Text Word] or Adult teeth[Text Word] or Dentition, permanent[Text Word] or Permanent Dentition[Text Word] or Dentition, Secondary[Text Word] or Secondary Dentition[Text Word] or Dentition, Adult[Text Word] or Adult Dentition[Text Word]	231456
2	Penicillin allergy[Text Word] or Penicillin allergic[Text Word] or Allergy to penicillin[Text Word] or Beta-Lactamase allergy[Text Word] or β -Lactam allergy[Text Word] or ((Penicillin[Text Word] or Beta-Lactamase[Text Word] or amoxicillin[Text Word] or β -Lactam[Text Word]) and (allergy[Text Word] or allergic[Text Word] or hypersensitivity[Text Word]))	4823
3	Antibiotic Prophylaxis[MeSH Terms] or Prophylaxis, Antibiotic[Text Word] or Premedication, Antibiotic[Text Word] or Antibiotic Premedication[Text Word] or Antibiotic Premedications[Text Word] or Premedications, Antibiotic[Text Word] or Antibiotic Prophylaxis[Text Word]	19544
4	(Macrolides[MeSH Terms] or Macrolides[Text Word] or Fidaxomicin[Text Word] or Lucensomycin[Text Word] or Maytansine[Text Word] or Mepartricin[Text Word] or Miocamycin[Text Word] or Natamycin[Text Word] or Nystatin[Text Word] or Oleandomycin[Text Word] or Troleandomycin[Text Word] or Oligomycins[Text Word] or Rutamycin[Text Word] or Sirolimus[Text Word] or Everolimus[Text Word] or Tacrolimus[Text Word] or Tylosin[Text Word]) and (Lincosamides[MeSH Terms] or Lincomycin[Text Word] or Lincosamides[Text Word] or Clindamycin[Text Word])	3074
5	((cost-benefit analysis[MeSH Terms] or (costs and cost analysis[MeSH Terms])) or technology assessment, biomedical[MeSH Terms] or Analyses, Cost-Benefit[Text Word] or Analysis, Cost-Benefit[Text Word] or Cost-Benefit Analyses[Text Word] or Cost Benefit Analysis[Text Word] or Analyses, Cost Benefit[Text Word] or Analysis, Cost Benefit[Text Word] or Cost Benefit Analyses[Text Word] or Cost Effectiveness[Text Word] or Effectiveness, Cost[Text Word] or Cost-Benefit Data[Text Word] or Cost Benefit Data[Text Word] or Data, Cost-Benefit[Text Word] or Cost-Utility Analysis[Text Word] or Analyses, Cost-Utility[Text Word] or Analysis, Cost-Utility[Text Word] or Cost Utility Analysis[Text Word] or Cost-Utility Analyses[Text Word] or Economic Evaluation[Text Word] or Economic Evaluations[Text Word] or Evaluation, Economic[Text Word] or Evaluations, Economic[Text Word] or Marginal Analysis[Text Word] or Analyses, Marginal[Text Word] or Analysis, Marginal[Text Word] or Marginal Analyses[Text Word] or Cost Benefit[Text Word] or (Costs[Text Word] and Benefits[Text Word])) or (Benefits[Text Word] and Costs[Text Word])) or Cost-Effectiveness Analysis[Text Word] or Analysis, Cost-Effectiveness[Text Word] or Cost Effectiveness Analysis[Text Word] or (Costs[Text Word] and Cost Analysis[Text Word])) or Affordability[Text Word] or Affordabilities[Text Word] or Cost-Minimization Analysis[Text Word] or Analyses, Cost-Minimization[Text Word] or Analysis, Cost-Minimization[Text Word] or Cost Minimization Analysis[Text Word] or Cost-Minimization Analyses[Text Word] or Pricing[Text Word] or Cost[Text Word] or Costs[Text Word] or Biomedical Technology Assessment[Text Word] or Technology Assessment, Health[Text Word] or Assessment, Health Technology[Text Word] or Assessments, Health Technology[Text Word] or Health Technology Assessment[Text Word] or Health Technology Assessments[Text Word] or Technology Assessments, Health[Text Word] or Assessment, Biomedical Technology[Text Word] or Assessments, Biomedical Technology[Text Word] or Biomedical Technology Assessments[Text Word] or Technology Assessments, Biomedical[Text Word] or Technology Assessment[Text Word] or Assessment, Technology[Text Word] or Assessments, Technology[Text Word] or Technology Assessments[Text Word] or Economics[Text Word] or willingness to pay[Text Word] or willingness-to-pay[Text Word] or health care cost[Text Word] or ICER[Text Word] or QALY[Text Word] or DALY[Text Word] or Quality-Adjusted-Life-Years[Text Word] or Quality Adjusted Life Years[Text Word] or Disability-Adjusted-Life-Years[Text Word] or Disability Adjusted Life-Years[Text Word] or Incremental Cost Effectiveness Ratio[Text Word]	907120
6	(pubmed books[filter] or Case Reports[ptyp] or Clinical Study[ptyp] or systematic[sb] or Government Document[ptyp] or Clinical Trial, Phase III[ptyp] or Clinical Trial, Phase II[ptyp] or Clinical Trial, Phase I[ptyp] or Clinical Trial Protocol[ptyp] or Clinical Trial[ptyp] or Clinical Trial, Phase IV[ptyp] or Comparative Study[ptyp] or Controlled Clinical Trial[ptyp] or English Abstract[ptyp] or Evaluation Studies[ptyp] or Guideline[ptyp] or Journal Article[ptyp] or	28461267

	Lecture[ptyp] or Meta-Analysis[ptyp] or Multicenter Study[ptyp] or Observational Study[ptyp] or Overall[ptyp] or Practice Guideline[ptyp] or Review[ptyp] or Randomized Controlled Trial[ptyp] or Pragmatic Clinical Trial[ptyp]	
7	("1999/01/01"[PDAT] : "2019/08/19"[PDAT])	17017913
8	(English[lang] or German[lang] or Portuguese[lang] or Spanish[lang])	26583508
9	#1 and #2 and #3 and #4 and #5 and #6 and #7 and #8	0

EMBASE

1	(Economic evaluation or biomedical technology assessment or health economics or quality adjusted life year or disability-adjusted life year).sh. or (Economic evaluation* or disease management or health economics or cost minimization analysis or cost minimization or cost-minimization or cost benefit analysis or cost-benefit or cost benefit or cost control or cost effectiveness analysis or cost-effectiveness or cost effectiveness or cost minimization analysis or cost of illness or cost utility analysis or cost utility or cost-utility or biomedical technology assessment or health technology assessment or biomedical technology assessment or high-cost technology or health care quality or health economics or dental economics or economics, dental or economics, hospital or hospital economics or economics, medical or medical economics or medical, nursing or nursing economics or economic aspect or health care concept or health care concepts or device economics or pharmacoeconomics or cost* or benefit* or pricing* or affordabilit* or marginal analysis or quality adjusted life year or qaly or quality-adjusted-life-year or disease burden or quality of life or disability adjusted life year or DALY or DALYs or disability-adjusted life year or disability-adjusted-life-year or ICER or Willingness to pay or Willingness-to-pay or Incremental cost effectiveness ratio or Incremental-cost-effectiveness-ratio).tw.	1936356
2	(Permanent tooth or Secondary dentition).sh or (adult dentition or dentition, permanent or permanent dentition or secondary dentition or adult teeth or adult tooth or dentes permanentes or permanent teeth or permanent tooth or secondary tooth or secondary teeth or tooth, permanent or tooth or teeth).tw.	151786
3	Penicillin allergy.sh or (Penicillin allergy or Penicillin allergic or Allergy to penicillin or Beta-Lactamase allergy or β -Lactam allergy).tw. or ((Penicillin.sh. or (penicillin or Beta-Lactamase or amoxicillin or β -Lactam).tw) and (allergy or allergic* or hypersensitivity).tw.)	5555
4	Antibiotic Prophylaxis.sh. or (Antibiotic Prophylaxis or Prophylaxis, Antibiotic or Premedication, Antibiotic or Antibiotic Premedication or Antibiotic Premedications or Premedications, Antibiotic or Antibiotic Prophylaxis).tw.	34062
5	(Macrolide or Fidaxomicin or Lucensomycin or Maytansine or Mepartricin or Miocamycin or Natamycin or Nystatin or Oleandomycin or Troleandomycin or Oligomycins or Rutamycin or Everolimus or Tacrolimus or Tylosin).sh. or (Macrolide* or Fidaxomicin or Lucensomycin or Maytansine or Mepartricin or Miocamycin or Natamycin or Nystatin or Oleandomycin or Troleandomycin or Oligomycins or Rutamycin or Sirolimus or Everolimus or Tacrolimus or Tylosin).tw.) and ((Lincosamide or lincomycin or Clindamycin).sh. or (Lincosamide or lincomycin or Clindamycin).tw.)	8605
6	1 and 2 and 3 and 4 and 5	0
7	Limit 6 to (english or german or portuguese or spanish)	0
8	Limit 7 to (article or article in press or books or chapter or "review")	0
9	Limit 8 to last 20 years	0
10	Limit 9 to embase	0